Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toujeo vs Tresiba in Insulin-Naive T2DM (BRIGHT)
NCT02738151Phase 4Completed
- Sponsor
- Sanofi
- Start
- May 2016
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change From Baseline in HbA1c at 24 weeks. Started May 2016; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02738151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02738151.